Option chain shows key data for Biostax's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Biostax.

Biostax (OTC:BTAX) Stock, Option Chain

Biostax Corp is a biotechnology company utilizing the Biostax Development Engine, is a developer and marketer of pharmaceutical, biotechnology and MedTech products that have a well-defined path to market. The company is focused on driving the development and commercialization of proprietary mechanisms to prevent, intercept and improve these diseases at affordable cost. It is a therapeutic and health tech agnostic, constantly seeking assets with low acquisition costs and high growth opportunities having significant clinical and commercial potential.

Biostax Corp

RBC Capital analyst Darko Mihelic maintains EQB (TSX:<a class="ticker" href="https://www.benzinga.com/stock/EQB#TSX">EQB</a>) with a Outperform and lowers the price target from C$153 to C$147.

News

Price Target

Analyst Ratings

TSX:EQB

RBC Capital Maintains Outperform on EQB, Lowers Price Target to C$147

D. Boral Capital analyst Jesse Sobelson maintains Pineapple Financial (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/PAPL#AMEX">PAPL</a>) with a Buy and maintains $5 price target.

PAPL

D. Boral Capital Maintains Buy on Pineapple Financial, Maintains $5 Price Target

Trading Ideas

ANET

Live On CNBC, Rob Sechan Announces Bought Arista Networks

RBC Capital analyst Daniel Perlin maintains TaskUs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TASK#NASDAQ">TASK</a>) with a Sector Perform and raises the price target from $18 to $20.

TASK

RBC Capital Maintains Sector Perform on TaskUs, Raises Price Target to $20

Beats Top End of 2024 Outlook and Affirms 2025 and 2026 Outlook
Please refer to the section entitled "Forward Looking Statements Disclosure" below for further discussion regarding the risks and uncertainties as well as other important information regarding Bristow's guidance. The following guidance also contains non-GAAP financial measures. Please read the section entitled "Non-GAAP Financial Measures" for further information.
Select financial results for 2024 are as follows (in USD, millions):
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">&nbsp; &nbsp;2024E(1)</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">2024A</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Revenues:</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Offshore Energy Services(2)</td>
<td colspan="1" rowspan="1">$959</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$966</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Government Services</td>
<td colspan="1" rowspan="1">$335</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$330</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Other Services</td>
<td colspan="1" rowspan="1">$120</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$120</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Total revenues</td>
<td colspan="1" rowspan="1">$1,414</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$1,416</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted EBITDA</td>
<td colspan="1" rowspan="1">$225</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$237</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Cash interest</td>
<td colspan="1" rowspan="1">$40</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$43</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Cash taxes</td>
<td colspan="1" rowspan="1">$23</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$21</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Maintenance capital expenditures</td>
<td colspan="1" rowspan="1">$18</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$18</td>
</tr>
</tbody>
</table>
</figure><figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="2" rowspan="1">__________________________&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">(1)</td>
<td colspan="1" rowspan="1">Reflects the mid-point of the previously issued 2024 financial outlook ranges. 2024E revvenues include approximately $31.0 million of reimbursable revenues due to the change in presentation from operating to total revenues.</td>
</tr>
<tr>
<td colspan="1" rowspan="1">(2)</td>
<td colspan="1" rowspan="1">OES includes approximately $12.7 million of Africa fixed wing revenues previously included in Other Services.</td>
</tr>
</tbody>
</table>
</figure>
In connection with its change in segment reporting, the Company also issued select financial guidance by segment for 2025 and 2026 as follows:
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">2025E</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">2026T</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Revenues:</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Offshore Energy Services</td>
<td colspan="1" rowspan="1">$950 - $1,060</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$975 - $1,165</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Government Services</td>
<td colspan="1" rowspan="1">$350 - $425</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$430 - $460</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Other Services</td>
<td colspan="1" rowspan="1">$120 - $130</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$120 - $150</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Total revenues</td>
<td colspan="1" rowspan="1">$1,420 - $1,615</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$1,525 - $1,775</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted Operating Income:</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Offshore Energy Services</td>
<td colspan="1" rowspan="1">$190 - $210</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$210 - $255</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Government Services</td>
<td colspan="1" rowspan="1">$45 - $55</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$75 - $85</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Other Services</td>
<td colspan="1" rowspan="1">$15 - $20</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$15 - $20</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Corporate</td>
<td colspan="1" rowspan="1">($30 - $40)</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">($30 - $40)</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$220 - $245</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$270 - $320</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted EBITDA</td>
<td colspan="1" rowspan="1">$230 - $260</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$275 - $335</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Cash interest</td>
<td colspan="1" rowspan="1">~$45</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">~$45</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Cash taxes</td>
<td colspan="1" rowspan="1">$25 - $30</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$25 - $30</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Maintenance capital expenditures</td>
<td colspan="1" rowspan="1">$15 - $20</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$20 - $25</td>
</tr>
</tbody>
</table>
</figure>
There are two main ways in which foreign currency fluctuations impact Bristow's reported financials. The first is primarily non-cash foreign exchange gains (losses) that are reported in the Other, net line on the statements of operations. These are related to the revaluation of certain balance sheet items, typically do not impact cash flows, and thus are excluded in the Adjusted EBITDA presentation. The second is through impacts to certain revenue and expense items, which impact the Company's cash flows. The primary exposure is the GBP/USD exchange rate.
Each £0.01 movement in the GBP/USD exchange rate would impact 2025E Adjusted EBITDA by +/- ~$1.2 million. The following table shows the GBP/USD exchange rate for each period presented.
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">2024A</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">2025E</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">2026T</td>
</tr>
<tr>
<td colspan="1" rowspan="1">(in millions, except for exchange rates)</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted EBITDA</td>
<td colspan="1" rowspan="1">$237</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$230 - $260</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$275 - $335</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Average GBP/USD exchange rate</td>
<td colspan="1" rowspan="1">1.28</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">1.26</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">1.26</td>
</tr>
</tbody>
</table>
</figure>

Guidance

VTOL

Bristow Group Reaffirms FY25 And FY26 Outlook, Sees FY25 Revenue $1.42B-$1.615B Vs $1.569B Est.; FY26 Revenue $1.525B-$1.775B Vs $1.702B Est.

D. Boral Capital analyst Jason Kolbert maintains Geovax Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOVX#NASDAQ">GOVX</a>) with a Buy and maintains $18 price target.

GOVX

D. Boral Capital Maintains Buy on Geovax Labs, Maintains $18 Price Target

HOOD

Live On CNBC, Bryn Talkington Announces Bought More Robinhood Markets

RBC Capital analyst Shagun Singh maintains Tandem Diabetes Care (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNDM#NASDAQ">TNDM</a>) with a Outperform and lowers the price target from $65 to $55.

TNDM

RBC Capital Maintains Outperform on Tandem Diabetes Care, Lowers Price Target to $55

WIIM

NTLA

Intellia Therapeutics shares are trading higher after the company reported better-than-expected Q4 financial results.

Bristow Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTOL#NYSE">VTOL</a>) reported quarterly earnings of $1.07 per share which beat the analyst consensus estimate of $0.58 by 84.48 percent. This is a 1628.57 percent increase over losses of $(0.07) per share from the same period last year. The company reported quarterly sales of $353.53 million which beat the analyst consensus estimate of $335.00 million by 5.53 percent. This is a 4.61 percent increase over sales of $337.93 million the same period last year.

Earnings

Earnings Beats

Bristow Group Q4 EPS $1.07 Beats $0.58 Estimate, Sales $353.53M Beat $335.00M Estimate

Ducommum shares are trading lower following a Q4 adjusted EPS miss.

Macquarie analyst Ross Compton maintains Maplebear (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CART#NASDAQ">CART</a>) with a Outperform and raises the price target from $52 to $55.

CART

Macquarie Maintains Outperform on Maplebear, Raises Price Target to $55

Global

Marathon Petroleum Says If Provisions Of Us Tariffs Are Maintained As Proposed, Expect Longer Term Impacts To Our Refining &marketing Margin Uncertain; Retaliatory Tariffs By Other Countries Or Other Potential Government Actions, To Likely Result In Further Adverse Impacts

Hamilton Beach Brands shares are trading higher after the company reported better-than-expected Q4 financial results.

RBC Capital analyst Logan Reich maintains Sweetgreen (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SG#NYSE">SG</a>) with a Outperform and lowers the price target from $45 to $30.

RBC Capital Maintains Outperform on Sweetgreen, Lowers Price Target to $30

VITL

Vital Farms shares are trading lower. The company reported Q4 financial results.

LMND

Lemonade shares are trading higher, rebounding from recent weakness. The stock fell on Tuesday after the company issued FY25 revenue guidance below estimates.

Wells Fargo analyst Michael Turrin maintains Snowflake (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNOW#NYSE">SNOW</a>) with a Overweight and raises the price target from $210 to $215.

SNOW

Wells Fargo Maintains Overweight on Snowflake, Raises Price Target to $215

INSW

International Seaways shares are trading lower after the company reported worse-than-expected Q4 EPS results.

LBRDA

LBRDK

Liberty Broadband shares are trading higher after the company reported better-than-expected Q4 sales results.

Health Care

Markets

Press Releases

Biostax Corp Announces Voluntary Delisting from OTC Pink Market and SEC Deregistration

BIOX

BTAX

Biostax

Comments

Biostax

Biostax (BTAX) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga